Lilly Asia Ventures leads AstraZeneca spinout's $100M push into China's growing R&D hub in Wuxi
Three years after launching with three preclinical assets from AstraZeneca’s R&D center in Shanghai and $132.5 million in cash, Dizal Pharma has drawn marquee new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.